SMMT compared with ACAD: revenue, margins and what each company keeps, and the suppliers and customers both name

SMMTSummit Therapeutics Inc.

Mkt capRevenueRevenue

ACADAcadia Pharmaceuticals Inc

Mkt capRevenueRevenue

Compare

SMMTSummit Therapeutics Inc.

ACADAcadia Pharmaceuticals Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

SMMT2 of 4 reports

1 of 1at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±8.4%▼−12.24%×1.45

Q2 FY26—▼−8.81%—

ACAD

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±15.9%▼−1.07%×0.07

Q2 FY26±11.9%▲+6.08%×0.51

= impliedSMMT realized, solidACAD realized, hatchedOne scale, both sides: full bar = 16%× = |realized| ÷ impliedspan: SMMT 104d · ACAD 252dSource: market data

May 7 '26

±13.4%

▲+5.03%

×0.37

Q1 FY26±9.4%▼−1.32%×0.14

SMMTSummit Therapeutics Inc.

16.33▲+15.09%· post 16.22

Mkt cap$13.1BRevenue—Revenue—

ACADAcadia Pharmaceuticals Inc

21.23▼−0.03%· post 21.23

ClosedNov 6 '26

Mkt cap$3.7BRevenue$342MQ3 FY26Revenue$1.1BFY25

Compare

ClosedNov 6 '26

SMMTSummit Therapeutics Inc.

ACADAcadia Pharmaceuticals Inc

16.33▲+15.09%post 16.22

Price

21.23▼−0.03%post 21.23

$13.1B

Mkt cap

$3.7B

—

Revenue

$342MQ3 FY26

—

Revenue

$1.1BFY25

SMMT16.33▲+15.09%vsACAD21.23▼−0.03%ClosedNov 6 '26